Trial reportGastrointestinal endoscopy2010
Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus.
Trial report in Gastrointestinal endoscopy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00282672 (Ablation of Intestinal Metaplasia Containing Dysplasia), which is not on this map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Randomized sham-controlled trials in endoscopy: a systematic review and meta-analysis of adverse events.Gastrointestinal endoscopy · 2017Pooled it
- ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.The American journal of gastroenterology · 2016Guideline
- Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.The American journal of gastroenterology · 2011Pooled it
- Improved specimen adequacy using jumbo biopsy forceps in patients with Barrett's esophagus.World journal of gastroenterology · 2015Trial
- Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus and Esophageal Cancer Using a Modified Delphi Process.The American journal of gastroenterology · 2026Article
- The Angular Spectrum of the Scattering Coefficient Map Reveals Subsurface Colorectal Cancer.Scientific reports · 2019Article
- Natural History of the Post-ablation Esophagus.Digestive diseases and sciences · 2018Review
- Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.United European gastroenterology journal · 2017Article
- Depth-resolved imaging of colon tumor using optical coherence tomography and fluorescence laminar optical tomography.Biomedical optics express · 2016Article
- Endoscopic Treatment of High-Grade Dysplasia and Intramucosal Esophageal Adenocarcinoma.Journal of laparoendoscopic & advanced surgical techniques. Part A · 2016Review
- Post-ablation surveillance in Barrett's esophagus: A review of the literature.World journal of gastroenterology · 2016Review
- Emerging Concepts for the Endoscopic Management of Superficial Esophageal Adenocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2016Review
- Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location.Gastrointestinal endoscopy · 2015Article
- Ablative therapy for esophageal dysplasia and early malignancy: focus on RFA.BioMed research international · 2014Review
- Diagnosis and management of Barrett's metaplasia: What's new.World journal of gastrointestinal endoscopy · 2012Article
- Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation.Gastroenterology · 2012Article
- Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos).Gastrointestinal endoscopy · 2012Article
- High-grade dysplasia and intramucosal adenocarcinoma in Barrett's esophagus: the role of endoscopic eradication therapy.Current opinion in gastroenterology · 2012Review
- Barrett's esophagus: endoscopic treatments II.Annals of the New York Academy of Sciences · 2011Article
- Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions.Therapeutics and clinical risk management · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAfter endoscopic radiofrequency ablation (RFA) of dysplastic Barrett's esophagus (BE), endoscopic biopsy samples are obtained to assess response to therapy. Whether these biopsies are of adequate depth to assess efficacy is unknown.
objectiveTo compare the depth of endoscopic biopsy samples after RFA with those of untreated controls and to determine the prevalence of subepithelial structures in endoscopic biopsy fragments.
designSecondary analysis of the AIM Dysplasia Trial, a multicenter, randomized, sham-controlled study.
settingNineteen treatment centers. PATIENTS: Subjects with dysplastic BE, either status post RFA or ablation naïve (sham). MAIN OUTCOME MEASUREMENTS: The proportion of biopsy samples demonstrating subepithelial structures, stratified by tissue type (columnar vs squamous) in sham- and RFA-treated subjects.
resultsA total of 5648 biopsy fragments were analyzed from 113 subjects (78 RFA, 35 sham; mean 50.0 fragments per subject). Most fragments (4653, 82.4%) contained subepithelium. Squamous biopsy samples from RFA and sham subjects demonstrated subepithelium at similar rates (78.4% vs 79.1%, respectively, P = not significant [NS]). Columnar biopsy samples from RFA and sham subjects also included subepithelium at similar rates (99.0% vs 98.8%, respectively, P = NS). Regardless of treatment assignment, more columnar than squamous biopsy samples demonstrated subepithelium (98.8% vs 78.5%, P < .001). LIMITATIONS: Biopsy samples were not individually mounted.
conclusionsIn both squamous and columnar tissue, endoscopic biopsy samples after RFA were as likely to demonstrate subepithelium as untreated controls. Almost 80% of all biopsy samples were adequate to evaluate for subsquamous intestinal metaplasia. The primary determinant of biopsy depth is the type of epithelium that underwent biopsy, with squamous less likely to yield subepithelium than columnar. Biopsy samples after RFA appear to be of adequate depth to assess response to therapy. (Clinical trial registration number NCT00282672.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.